Market news

Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 2.8% in the afternoon session after Argus analyst John Eade initiated coverage on the company with a Buy rating.

10x Genomics Inc (TXG) shares rose 3.1% in Monday trading after Argus Research initiated coverage of

10x Genomics (TXG) has an average rating of overweight and mean price target of $58.80, according to

Shehnaaz Suliman, Director, on September 22, 2026, sold 5,723 shares in 10x Genomics (TXG) for $464,

Detailed price information for Zimmer Biomet Holdings (ZBH-N) from The Globe and Mail including charting and trades.

10x Genomics (TXG) has an average rating of overweight and mean price target of $52.13, according to

10x Genomics has delivered an unusually strong share price run over the past year, which puts a spotlight on whether the current valuation lines up with its sales base. With the stock now well above where it traded in prior years, investors are increasingly asking how much of the business story is already reflected in the price. Over the last 12 months, the stock has returned roughly 4.9x, which raises the question of how much future sales progress is already being assumed in the current...

A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic conditions across broader equity markets drove a rotation into healthcare, lifting the sector index by approximately 7% quarter-to-date to reach a 5% valuation premium.

Adam Taich, Chief Financial Officer, on September 09, 2026, sold 46,388 shares in 10x Genomics (TXG)

John R Stuelpnagel, Director, on September 03, 2026, sold 20,000 shares in 10x Genomics (TXG) for $1

10x Genomics (TXG) is offering a compelling product cycle but its two franchises are pulling in oppo

10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position as it seeks added damages and a U.S. injunction.

10x Genomics (TXG) said a Delaware federal jury awarded the company more than $4.8 million after fin

10x Genomics sells instruments, consumables and services used to analyze biological information. Read why TXG stock is upgraded to a buy.

On August 6, 10x Genomics (NASDAQ:TXG) reported second-quarter revenue of $151 million, boosted by a $1.6 million settlement payment from Takara. Strip that out and revenue grew just 3% year-over-year to $149.4 million, a modest number next to the real headline of the quarter: a brand-new instrument platform called Atera, where booked orders have exceeded […]

10x Genomics (TXG) has drawn fresh investor attention after raising its 2026 revenue outlook on 6 August, citing strong early orders for its new Atera platform and ongoing integration of Proteintech Genomics. See our latest analysis for 10x Genomics. The market reaction around 10x Genomics’ updated 2026 outlook and Atera launch has been choppy, with a 1-day share price return that declined 3.54%, yet shorter term momentum remains strong given a 30-day share price return of 28.23% and a 90-day...

10x Genomics’ second quarter results came in above Wall Street’s expectations for both revenue and profitability, yet the market responded negatively. Management attributed the year-over-year revenue decline to lower instrument sales, particularly as customers moderated purchases of current spatial products in anticipation of the upcoming Atera platform. CEO Serge Saxonov emphasized the strong momentum in Chromium consumables and growing engagement across both academic and biopharma customers, w

Motley Fool Press Release.

Detailed price information for 10X Genomics Inc (TXG-Q) from The Globe and Mail including charting and trades.

Detailed price information for Arvinas Inc (ARVN-Q) from The Globe and Mail including charting and trades.

Tipranks Press Release.